Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discounts will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Bayer will acquire full control of the cell-therapy developer BlueRock Therapeutics in a deal that values the company at up to $1 billion. Bayer and Versant Ventures established BlueRock in 2016 to develop regenerative medicines based on induced pluripotent stem cells (iPSCs). Bayer is now buying Versant’s 59% stake. Bayer recently committed $215 million to Century Therapeutics, another Versant-backed iPSC firm.
This article has been sent to the following recipient: